UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Roca-Fernandez A
(2022)
Liver disease is a significant risk factor for cardiovascular outcomes - a UK Biobank study
Schneider CV
(2020)
Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*MZ vs Pi*ZZ genotype) and Noncarriers.
in Gastroenterology
Lupi AS
(2022)
Local genetic covariance between serum urate and kidney function estimated with Bayesian multitrait models.
in G3 (Bethesda, Md.)
Palmer MR
(2021)
Loci identified by a genome-wide association study of carotid artery stenosis in the eMERGE network.
in Genetic epidemiology
Sutin AR
(2023)
Loneliness and risk of all-cause, Alzheimer's, vascular, and frontotemporal dementia: a prospective study of 492,322 individuals over 15 years.
in International psychogeriatrics
Zajner C
(2021)
Loneliness is linked to specific subregional alterations in hippocampus-default network covariation
in Journal of Neurophysiology
McPeake J
(2021)
Long term outcomes following critical care hospital admission: A prospective cohort study of UK biobank participants
in The Lancet Regional Health - Europe
Gao X
(2023)
Long-Term Air Pollution, Genetic Susceptibility, and the Risk of Depression and Anxiety: A Prospective Study in the UK Biobank Cohort.
in Environmental health perspectives
Lee S
(2022)
Long-term cardiovascular outcomes of gestational diabetes mellitus: a prospective population-based UK Biobank study
in American Journal of Obstetrics and Gynecology
Lee SM
(2022)
Long-term cardiovascular outcomes of gestational diabetes mellitus: a prospective UK Biobank study.
in Cardiovascular diabetology
Honigberg MC
(2019)
Long-Term Cardiovascular Risk in Women With Hypertension During Pregnancy.
in Journal of the American College of Cardiology
Gaastra B
(2022)
Long-Term Cognitive Outcome following Aneurysmal Subarachnoid Haemorrhage.
in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
Corcoran NM
(2022)
Long-term conditions, multimorbidity and colorectal cancer risk in the UK Biobank cohort.
in Journal of multimorbidity and comorbidity
Harrison S
(2021)
Long-term cost-effectiveness of interventions for obesity: A mendelian randomisation study.
in PLoS medicine
Li FR
(2023)
Long-term exposure to air pollution and incident non-alcoholic fatty liver disease and cirrhosis: A cohort study.
in Liver international : official journal of the International Association for the Study of the Liver
Li FR
(2022)
Long-term exposure to air pollution and risk of incident inflammatory bowel disease among middle and old aged adults.
in Ecotoxicology and environmental safety
Gaastra B
(2022)
Long-term fatigue following aneurysmal subarachnoid haemorrhage and the impact on employment.
in European journal of neurology
Nguyen TNM
(2022)
Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer's disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies.
in Alzheimer's research & therapy
Muralidharan A
(2022)
Long-term male-specific chronic pain via telomere- and p53-mediated spinal cord cellular senescence
in Journal of Clinical Investigation
Wang N
(2021)
Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease.
in European heart journal
Palpatzis E
(2022)
Longitudinal association of apolipoprotein E and sleep with incident dementia.
in Alzheimer's & dementia : the journal of the Alzheimer's Association
Brayner B
(2022)
Longitudinal Associations Between Fat-Derived Dietary Patterns and Early Markers of Cardiovascular Disease Risk in the UK Biobank Study.
in Journal of the American Heart Association
Spathis D
(2022)
Longitudinal cardio-respiratory fitness prediction through wearables in free-living environments.
in NPJ digital medicine
Ambikairajah A
(2020)
Longitudinal Changes in Fat Mass and the Hippocampus.
in Obesity (Silver Spring, Md.)
Marriott RJ
(2022)
Longitudinal changes in serum testosterone and sex hormone-binding globulin in men aged 40-69 years from the UK Biobank.
in Clinical endocrinology
Allen RJ
(2023)
Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study.
in The Lancet. Respiratory medicine
Ganjdanesh A
(2022)
LONGL-Net: temporal correlation structure guided deep learning model to predict longitudinal age-related macular degeneration severity.
in PNAS nexus
Vergnano M
(2020)
Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease.
in American journal of human genetics
Paludan-Muller C
(2022)
Loss-of-function variants in founder population highlight atrial myopathy as susceptibility to atrial fibrillation
in European Heart Journal
Luo J
(2023)
Low leukocyte mitochondrial DNA abundance drives atherosclerotic cardiovascular diseases: a cohort and Mendelian randomization study.
in Cardiovascular research
Olivo G
(2019)
Low neuroticism and cognitive performance are differently associated to overweight and obesity: A cross-sectional and longitudinal UK Biobank study.
in Psychoneuroendocrinology
XUE X
(2022)
Low Regional Homogeneity of Intrinsic Cerebellar Activity in Ankle Instability: An Externally Validated rs-fMRI Study
in Medicine & Science in Sports & Exercise
Pilling LC
(2021)
Low Vitamin D Levels and Risk of Incident Delirium in 351,000 Older UK Biobank Participants.
in Journal of the American Geriatrics Society
Cupido A
(2022)
Low-Density Lipoprotein Cholesterol Attributable Cardiovascular Disease Risk Is Sex Specific
in Journal of the American Heart Association
Shi H
(2022)
Low-grade inflammation as mediator between diet and behavioral disinhibition: A UK Biobank study.
in Brain, behavior, and immunity
Raisi-Estabragh Z
(2023)
Lower birth weight is linked to poorer cardiovascular health in middle-aged population-based adults.
in Heart (British Cardiac Society)
Jensen M
(2022)
Lower lymphocyte count is associated with increased risk of Parkinson's disease
in Journal of Neurology, Neurosurgery & Psychiatry
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |